Vertex Prices Telaprevir At $49,200 For Course Of Therapy
This article was originally published in The Pink Sheet Daily
In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.
You may also be interested in...
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
In its inaugural Drug Trends Quarterly, Express Scripts finds that prices for branded pharmaceuticals are growing at a faster pace than the Consumer Price Index and the gap between branded and generic drug prices is at its widest point since the pharmacy benefit manager began calculating price indexes for each in 2008.
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.